AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
Analysts expect the Latham, New York-based company to report a quarterly loss at 15 cents per share, versus a year-ago loss of 12 cents per share. AngioDynamics is projected to post quarterly revenue of $67.93 million, according to data from Benzinga Pro.
On Sept. 3, AngioDynamics announced CE Mark approval for Auryon System in Europe.
AngioDynamics shares gained 0.3% to close at $7.65 on Wednesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
- HC Wainwright analyst Yi Chen reiterated a Buy rating with a price target of $14 on Sept. 20. This analyst has an accuracy rate of 63%.
- Oppenheimer analyst Steven Lichtman upgraded the stock from Perform to Outperform with a price target of $12 on April 5. This analyst has an accuracy rate of 74%.
- Raymond James analyst Jayson Bedford maintained an Outperform rating and cut the price target from $12 to $10 on Jan. 9. This analyst has an accuracy rate of 71%.
Considering buying ANGO stock? Here’s what analysts think:
Read This Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.